SPONSORED BIOGRAPHIES INTELLECTUAL PROPERTY
PETER J. ARMENIO, P.C. QUINN EMANUEL URQUHART & SULLIVAN, LLP Partner Co-Chair, Global Life Sciences Practice New York Office Tel: 212 849 7000 Email: [email protected] Peter is a trial lawyer and Co-Chair of Quinn Emanuel’s Global Life Sciences Practice. Peter focuses his practice on patent infringement actions regarding pharmaceuticals, medical devices, and biotechnology, and has served as lead counsel in Federal courts across the country and in national and international arbitrations. As lead counsel representing defendants, Peter has defeated over $1 billion in damages claims at trial or arbitration, and defeated another over $1 billion in damages claims on summary judgment or as a result of other pre-trial procedures. As lead counsel representing plaintiffs, Peter has protected over $10 billion in sales for his branded pharmaceutical clients and won jury trial damages for his medical device clients. Peter has been recognized by a number of guides and rankings, which include client comments that Peter is a “talented patent litigator” and that he “handles cases expertly and efficiently, obtaining great results at a reasonable cost – often through facilitating early wins.” Notable Representations Lead trial counsel for Meda Pharmaceuticals Inc. in multiple HatchWaxman patent infringement litigations regarding its ASTEPRO® brand anti-allergy nasal spray, obtaining consent judgments with injunctions against Apotex and Zydus (D.N.J. 2012). Lead trial counsel for Covidien in patent infringement litigation brought against its VERSAPORT™ PLUS surgical trocar products, obtaining summary judgment of non-infringement (C.D. Cal. 2012). Lead trial counsel for Meda Pharmaceuticals Inc. in a senior executive employment arbitration, obtaining a Panel judgment in favor of Meda on all counts (AAA arbitration 2011). Lead trial and appellate counsel for H. Lundbeck A/S and Forest Laboratories Inc. in patent infringement litigation brought against the manufacture of their LEXAPRO® and CELEXA® brand antidepressants, obtaining JMOL of patent invalidity and a F ??????
???????????????L??8?d???????????????
?????????1??????????????????Q??!???????? ????1@????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????Q???????????1??????????????????M???????A?????
???????????????!????]????????????????????????????????????????
1I%9c
??????????????????????????????????????????????????????????????????????????????8?(???????????1?????????????????? ????M???-????????????????????????????????????????????????????????????????!????]????????????????????????????15%
Q3
????????????????????????????????????????????????8?(???????1??????????????????5????A????????????%??????????????!???]????????????????????????????????????????MQ1%;
?????????????????????????????????????????????????????????????????????????????????????????????1?????????????????? ?????M?????????
??????????????????????????????????????????????????????????????1% IQ
??????QaUL?1% IQ
??????????????????????????????????Q????????????????????????????????]%A